Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

34.660
-2.240-6.07%
Volume:12.41M
Turnover:443.79M
Market Cap:12.27B
PE:-38.94
High:37.840
Open:36.900
Low:34.240
Close:36.900
52wk High:67.500
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:0.43
T/O Rate:3.51%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:2.01
PE(LYR):-38.94
PS:4.37

Loading ...

Everest Med inks exclusive Greater China deal with Corxel for FDA-approved presbyopia therapy LNZ100

Bulletin Express
·
Jun 08

Everest Medicines - to Pay Upfront, Milestone Payments and Tiered Royalties for Lnz100

THOMSON REUTERS
·
Jun 08

Everest Medicines - Enters Agreement for Exclusive Lnz100 License in Greater China

THOMSON REUTERS
·
Jun 08

Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Weakness

Simply Wall St.
·
Jun 06

Everest Med Chairman Wu Yifang Acquires Additional 20,000 Shares at HK$28.8 Each

Stock News
·
Jun 05

Everest Medicines' Substantial Shareholder Boosts Stake

MT Newswires Live
·
Jun 04

Everest Medicines Says CBC Group Buys 690,000 Co Shares For HK$20 MLN

Reuters
·
Jun 04

Major Shareholder Boosts Stake in Everest Med with Purchase of 690,000 Shares

Stock News
·
Jun 04

EVEREST MED: CBC Group Boosts Stake with HK$20.00 Million On-Market Purchase of 690,000 Shares

Bulletin Express
·
Jun 04

Everest Medicines - Cbc Group Purchases 690,000 Everest Medicines Shares for HK$20 Mln at HK$28.93 per Share

THOMSON REUTERS
·
Jun 04

EVEREST MED Shares Surge on Licensing Deal for Drug Candidate

Stock News
·
Jun 03

Everest Medicines schedules 26 June 2026 virtual AGM; proposes 10% buy-back mandate, 20% issuance limit, five director re-elections and Ernst & Young reappointment

Bulletin Express
·
Jun 02

EVEREST MED Calls 17 June 2026 Virtual EGM to Ratify Share Purchase Agreement

Bulletin Express
·
Jun 02

Everest Medicines Plans US$250 Million Related-Party Buyout of Hasten Biopharma’s APAC Portfolio

Bulletin Express
·
Jun 02

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Reuters
·
Jun 02

EVEREST MED Secures $112.5 Million Upfront Payment in Licensing Deal for Kidney Disease Drug Candidate with Travere

Stock News
·
Jun 02

Travere Therapeutics licenses Everest Medicines’ civorebrutinib outside China in USD 112.5 million deal

Reuters
·
Jun 02

Everest Medicines delays circular to 3 June 2026, confirms 17 June EGM with 12–17 June book closure

Bulletin Express
·
May 29

Everest MED Surges Over 6% as Nefecon to Present 23 New Research Findings at ERA 2026

Stock News
·
May 29

Everest Medicines Insiders Placed Bullish Bets Worth CN¥98.2m

Simply Wall St.
·
May 28